A diversified clinical pipeline designed to address inflammation and immune dysregulation in conditions that affect women.
IVF
Several studies have indicated that dysbiosis of the reproductive tract leads to immune activation and inflammation, negatively affecting IVF success. Currently there are limited therapeutic options for women with dysbiosis undergoing IVF.
Preterm Birth
It has been demonstrated that an early inflammatory cascade increases the risk of preterm birth. Current intervention options focus on managing preterm labor and delaying delivery for a short period of time.
Other Disease Areas
Many other conditions affecting women’s health are driven by local immune dysregulation. Novel therapeutic opportunities will be elucidated through Freya’s platform.
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|
FB301
FB301 is advancing into Phase 2 for IVF-related embryo implantation failure, following successful proof-of-concept and Phase 1 trials
FB401
FB401 is advancing into Phase 2, targeting preterm birth, with bacterial vaginosis serving as the initial proof-of-concept patient population
Other programs
Freya is leveraging the team’s deep experience in drug development, immunology and women’s health to broaden its reach across high unmet-need indications including endometriosis.
Copyright © Freya
